TABLE 2.

Factors associated with fatigue in patients with PD.

	Unadjusted model			Adjusted model
	B	95%CI	P-value	B	95%CI	P-value
Age	0.990	0.970–1.010	0.320	0.981	0.960–1.002	0.078
Male sex	0.819	0.541–1.239	0.344	0.783	0.520–1.180	0.164
Disease duration	1.023	0.927–1.128	0.656	0.906	0.794–1.035	0.145
Education	0.974	0.922–1.030	0.354
LEDD	1.001	1.000–1.001	0.031*	1.001	1.000–1.002	0.153
Use of levodopa	1.145	0.826–1.587	0.416
Use of dopamine agonist	1.140	0.848–1.532	0.386
Use of MAO-B inhibitor	0.766	0.441–1.330	0.343
Use of antidepressant	0.979	0.438–2.191	0.960
FAB	0.917	0.833–1.009	0.076	0.957	0.837–1.093	0.515
MOCA	0.948	0.892–1.007	0.083	0.990	0.916–1.070	0.806
Sleep disorders	3.450	2.319–5.133	<0.001*	2.446	1.580–3.788	<0.001*
RBD	0.984	0.647–1.496	0.940
HAMD	1.084	1.052–1.117	<0.001*	1.001	0.951–1.049	0.969
HAMA	1.109	1.072–1.148	<0.001*	1.072	1.016–1.131	0.011*
LARS	1.024	1.006–1.043	0.009*	1.010	0.987–1.033	0.391
UPDRS III	1.038	1.022–1.053	<0.001*	1.029	1.010–1.049	0.003*
Follow-up time in years	1.017	0.891–1.162	0.798

PD, Parkinson’s disease; LEDD, levodopa equivalent daily dose; MAO-B, Monoamine oxidase type B; FAB, Frontal Assessment Battery; MOCA, Montreal Cognitive Assessment; RBD, Rapid eye movement behavior disorder; HAMD, Hamilton Depression Rating Scale; HAMA, Hamilton Anxiety Rating Scale; LARS, Lille Apathy Rating Scale; UPDRS, Unified Parkinson’s Disease Rating Scale. *Significant difference.